Ace­lyrin sets out for a 2021-sized IPO for Cal­i­for­nia biotech’s PhI­II drug

Drug li­cen­sor and de­vel­op­er Ace­lyrin re­vealed more of its IPO plans Mon­day morn­ing, map­ping out what could be one of the biggest biotech IPOs in the past few years if it rais­es $370 mil­lion by pric­ing at the high end of its pro­posed range.

The Cal­i­for­nia biotech aims to sell 20.6 mil­lion shares of com­mon stock be­tween $16 and $18 apiece and trade on Nas­daq as “$SLRN,” Ace­lyrin re­vealed Mon­day morn­ing as it kicks off a road­show to court po­ten­tial in­vestors. The im­munol­o­gy biotech plans to of­fer un­der­writ­ers a 30-day op­tion to buy up to 3.09 mil­lion more shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER